natgillin/translations-raw huggingface dataset:
CHMP besluttede, at fordelene ved Extavia opvejer risiciene, og anbefalede udstedelse af markedsføringstilladelse.
The CHMP decided that Extavia’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Fablyn opvejer risiciene, og anbefalede udstedelse af markedsføringstilladelse.
The CHMP decided that Fablyn’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Fabrazyme opvejer risiciene, og anbefalede udstedelse af en markedsføringstilladelse.
The CHMP decided that Fabrazyme’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Fendrix opvejer risiciene, og anbefalede udstedelse af markedsføringstilladelse for Fendrix.
The CHMP decided that Fendrix’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Ferriprox er større end risiciene, og anbefalede udstedelse af markedsføringstilladelse for Ferriprox.
The CHMP decided that Ferriprox’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Fertavid er større end risiciene, og anbefalede udstedelse af markedsføringstilladelse for Fertavid.
The CHMP decided that Fertavid’s benefits are greater than its risks and recommended that Fertavid be given marketing authorisation.
CHMP besluttede, at fordelene ved Firazyr er større end risiciene, og anbefalede udstedelse af markedsføringstilladelse for Firazyr.
The CHMP decided that Firazyr’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Focetria opvejer risiciene, og anbefalede udstedelse af markedsføringstilladelse for Focetria.
The CHMP decided that Focetria’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Foclivia opvejer risiciene, og anbefalede udstedelse af en markedsføringstilladelse for Foclivia.
The CHMP decided that Foclivia’s benefits are greater than its risk and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Forsteo opvejer risiciene, og anbefalede udstedelse af en markedsføringstilladelse for Forsteo.
The CHMP concluded that Forsteo’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Fosavance opvejer risiciene, og anbefalede udstedelse af markedsføringstilladelse.
The CHMP decided that Fosavance’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Fycompa opvejer risiciene, og anbefalede udstedelse af en markedsføringstilladelse.
Therefore, the CHMP decided that Fycompa’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Ganfort opvejer risiciene, og anbefalede udstedelse af en markedsføringstilladelse for Ganfort.
The CHMP decided that Ganfort’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Gardasil opvejer risiciene, og anbefalede udstedelse af en markedsføringstilladelse for Gardasil.
The CHMP decided that Gardasil’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Glivec opvejer risiciene, og anbefalede udstedelse af markedsføringstilladelse.
The CHMP decided that Glivec’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Glustin opvejer risiciene, og anbefalede udstedelse af markedsføringstilladelse.
The CHMP decided that Glustin’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved GONAL-f er større end risiciene, og anbefalede udstedelse af markedsføringstilladelse for GONAL-f.
The CHMP decided that GONAL-f’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Helixate NexGen opvejer risiciene, og anbefalede udstedelse af markedsføringstilladelse for Helixate NexGen.
The CHMP decided that Helixate NexGen’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Herceptin opvejer risiciene, og anbefalede udstedelse af markedsføringstilladelse.
The CHMP decided that Herceptin’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Hirobriz Breezhaler opvejer risiciene, og anbefalede udstedelse af markedsføringstilladelse for Hirobriz Breezhaler.
The CHMP decided that Hirobriz Breezhaler’s benefits are greater than its risks and recommended that Hirobriz Breezhaler be given marketing authorisation.
CHMP besluttede, at fordelene ved Humira opvejer risiciene, og anbefalede udstedelse af en markedsføringstilladelse for Humira.
The CHMP decided that Humira’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Hycamtin opvejer risiciene, og anbefalede udstedelse af en markedsføringstilladelse for Hycamtin.
The CHMP decided that Hycamtin’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Ilaris opvejer risiciene, og anbefalede udstedelse af markedsføringstilladelse for Ilaris.
The CHMP decided that Ilaris’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Imprida opvejer risiciene, og anbefalede udstedelse af en markedsføringstilladelse for Imprida.
The CHMP decided that Imprida’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Increlex opvejer risiciene, og anbefalede udstedelse af en markedsføringstilladelse.
The CHMP decided that Increlex’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Infanrix hexa er større end risiciene, og anbefalede udstedelse af markedsføringstilladelse for Infanrix hexa.
The CHMP decided that Infanrix hexa’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Infanrix Penta er større end risiciene, og anbefalede udstedelse af markedsføringstilladelse for Infanrix Penta.
The CHMP decided that Infanrix Penta’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Inovelon er større end risiciene, og anbefalede udstedelse af markedsføringstilladelse for Inovelon.
The CHMP decided that Inovelon’s benefits are greater that its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Instanyl opvejer risiciene, og anbefalede udstedelse af en markedsføringstilladelse for Instanyl.
The CHMP decided that Instanyl’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Insulatard opvejer risiciene, og anbefalede udstedelse af en markedsføringstilladelse for Insulatard.
The CHMP decided that Insulatard’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Insuman opvejer risiciene ved behandling af type 1- og type 2- diabetes.
The CHMP decided that Insuman’s benefits are greater than its risks for the treatment of type 1 and type 2 diabetes.
CHMP besluttede, at fordelene ved Intanza opvejer risiciene, og anbefalede udstedelse af markedsføringstilladelse.
The CHMP decided that Intanza’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Intelence opvejer risiciene, og anbefalede udstedelse af markedsføringstilladelse.
The CHMP decided that Intelence’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Invega opvejer risiciene hos voksne, og anbefalede udstedelse af markedsføringstilladelse for skizofreni og skizoaffektiv lidelse.
The CHMP decided that Invega’s benefits are greater than its risks in adults and recommended that it be given marketing authorisation for schizophrenia and schizoaffective disorder.
CHMP besluttede, at fordelene ved Invirase opvejer risiciene, og anbefalede udstedelse af markedsføringstilladelse for Invirase.
The CHMP decided that Invirase’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Ioa opvejer risiciene, og anbefalede udstedelse af markedsføringstilladelse.
The CHMP decided that the benefits of Ioa are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Irbesartan Hydrochlorothiazid Zentiva opvejer risiciene, og anbefalede udstedelse af markedsføringstilladelse.
The CHMP decided that Irbesartan Hydrochlorothiazide Zentiva’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Irbesartan Zentiva opvejer risiciene, og anbefalede udstedelse af markedsføringstilladelse.
The CHMP decided that Irbesartan Zentiva’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Iscover opvejer risiciene, og anbefalede udstedelse af markedsføringstilladelse.
The CHMP decided that Iscover’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Isentress opvejer risiciene, og anbefalede udstedelse af en markedsføringstilladelse for Isentress.
The CHMP decided that Isentress’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Ivemend er større end risiciene, og anbefalede udstedelse af markedsføringstilladelse for Ivemend.
The CHMP decided that Ivemend’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Jakavi opvejer risiciene og anbefalede udstedelse af en markedsføringstilladelse for Jakavi.
The CHMP decided that Jakavi’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Janumet opvejer risiciene, og anbefalede udstedelse af markedsføringstilladelse.
CHMP decided that Janumet’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Januvia opvejer risiciene, og anbefalede udstedelse af markedsføringstilladelse.
The CHMP decided that Januvia’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Javlor er større end risiciene, og anbefalede udstedelse af markedsføringstilladelse.
The CHMP decided that Javlor’s benefits are greater than its risks and recommended that Javlor be given marketing authorisation.
CHMP besluttede, at fordelene ved Kaletra opvejer risiciene, og anbefalede udstedelse af markedsføringstilladelse.
The CHMP decided that Kaletra’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Kalydeco overstiger risiciene, og anbefalede udstedelse af en markedsføringstilladelse for Kalydeco.
The CHMP concluded that the benefits of Kalydeco are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Karvea opvejer risiciene, og anbefalede udstedelse af markedsføringstilladelse.
The CHMP decided that Karvea’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Karvezide opvejer risiciene, og anbefalede udstedelse af markedsføringstilladelse.
The CHMP decided that Karvezide’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Keppra opvejer risiciene, og anbefalede udstedelse af markedsføringstilladelse.
The CHMP decided that Keppra’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Kinzalmono opvejer risiciene, og anbefalede udstedelse af en markedsføringstilladelse.
The CHMP decided that Kinzalmono’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Kogenate Bayer opvejer risiciene, og anbefalede udstedelse af markedsføringstilladelse for Kogenate Bayer.
The CHMP decided that Kogenate Bayer’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Kuvan opvejer risiciene, og anbefalede udstedelse af markedsføringstilladelse.
The CHMP decided that Kuvan’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Lantus opvejer risiciene, og anbefalede udstedelse af markedsføringstilladelse.
The CHMP decided that Lantus’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Leflunomide Winthrop opvejer risiciene, og anbefalede udstedelse af en markedsføringstilladelse for Leflunomide Winthrop.
The CHMP decided that Leflunomide Winthrop’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Leganto opvejer risiciene, og anbefalede udstedelse af markedsføringstilladelse.
The CHMP decided that Leganto’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Levemir opvejer risiciene, og anbefalede udstedelse af markedsføringstilladelse.
The CHMP decided that Levemir’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Levitra opvejer risiciene, og anbefalede udstedelse af en markedsføringstilladelse for Levitra.
The CHMP decided that Levitra’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Levodopa/Carbidopa/Entacapone Orion opvejer risiciene, og anbefalede udstedelse af markedsføringstilladelse.
The CHMP decided that Levodopa/Carbidopa/Entacapone Orion’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Livensa opvejer risiciene, og anbefalede udstedelse af markedsføringstilladelse.
The CHMP decided that Livensa’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Lucentis opvejer risiciene, og anbefalede udstedelse af en markedsføringstilladelse for Lucentis.
The CHMP decided that Lucentis’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Luminity opvejer risiciene, og anbefalede udstedelse af en markedsføringstilladelse for Luminity.
The CHMP decided that Luminity’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Lyrica opvejer risiciene, og anbefalede udstedelse af markedsføringstilladelse.
The CHMP decided that Lyrica’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved lægemidlet opvejer risiciene, og anbefalede udstedelse af en markedsføringstilladelse for Methylthioniniumchlorid Proveblue.
The CHMP decided that the medicine’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved M-M-RVAXPRO opvejer risiciene, og anbefalede udstedelse af markedsføringstilladelse.
The CHMP decided that M-M-RVAXPRO’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Macugen opvejer risiciene, og anbefalede udstedelse af en markedsføringstilladelse for Macugen.
The CHMP decided that Macugen’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Memantine Merz opvejer risiciene, og anbefalede udstedelse af markedsføringstilladelse.
The CHMP decided that Memantine Merz’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Micardis opvejer risiciene, og anbefalede udstedelse af en markedsføringstilladelse.
The CHMP decided that Micardis’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Mirapexin er større end risiciene, og anbefalede udstedelse af markedsføringstilladelse for Mirapexin.
The CHMP decided that Mirapexin’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Mixtard opvejer risiciene, og anbefalede udstedelse af en markedsføringstilladelse for Mixtard.
The CHMP decided that Mixtard’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Myozyme er større end risiciene, og anbefalede udstedelse af markedsføringstilladelse for Myozyme.
The CHMP decided that Myozyme’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Neoclarityn opvejer risiciene ved lindring af symptomer forbundet med allergisk rhinitis eller urticaria og anbefalede udstedelse af markedsføringstilladelse.
The CHMP decided that Neoclarityn’s benefits are greater than its risks for the relief of symptoms associated with allergic rhinitis or urticaria and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved NeoRecormon opvejer risiciene, og anbefalede udstedelse af en markedsføringstilladelse for NeoRecormon.
The CHMP decided that NeoRecormon’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Neulasta opvejer risiciene, og anbefalede udstedelse af markedsføringstilladelse.
The CHMP decided that Neulasta’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Neupro opvejer risiciene, og anbefalede udstedelse af markedsføringstilladelse.
The CHMP decided that Neupro’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved NeuroBloc opvejer risiciene, og anbefalede udstedelse af markedsføringstilladelse.
The CHMP decided that NeuroBloc’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Nevanac opvejer risiciene og anbefalede udstedelse af en markedsføringstilladelse.
The CHMP decided that Nevanac’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Nexavar opvejer risiciene, og anbefalede udstedelse af en markedsføringstilladelse for Nexavar.
The CHMP decided that Nexavar’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Norvir opvejer risiciene, og anbefalede udstedelse af en markedsføringstilladelse for Norvir.
The CHMP decided that Norvir’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved NovoMix opvejer risiciene, og anbefalede udstedelse af markedsføringstilladelse.
The CHMP decided that NovoMix’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Noxafil opvejer risiciene, og anbefalede udstedelse af en markedsføringstilladelse for Noxafil.
The Committee decided that Noxafil’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Onbrez Breezhaler opvejer risiciene, og anbefalede udstedelse af markedsføringstilladelse for Onbrez Breezhaler.
The CHMP decided that Onbrez Breezhaler’s benefits are greater than its risks and recommended that Onbrez Breezhaler be given marketing authorisation.
CHMP besluttede, at fordelene ved Opatanol opvejer risiciene ved behandling af øjensymptomer ved sæsonbundet allergisk betændelse i øjets bindehinde (konjunktivitis), og anbefalede udstedelse af en markedsføringstilladelse for Opatanol.
The CHMP decided that Opatanol’s benefits are greater than its risks for the treatment of ocular signs and symptoms of seasonal allergic conjunctivitis and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Optaflu opvejer risiciene, og anbefalede udstedelse af en markedsføringstilladelse for Optaflu.
The CHMP decided that Optaflu’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Ornalutran er større end risiciene, og anbefalede udstedelse af markedsføringstilladelse for Orgalutran.
The CHMP decided that Orgalutran’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Osigraft er større end risiciene, og anbefalede udstedelse af markedsføringstilladelse for Osigraft.
The CHMP decided that Osigraft’s benefits are greater than its risks and recommended that Osigraft be given marketing authorisation.
CHMP besluttede, at fordelene ved Oslif Breezhaler opvejer risiciene, og anbefalede udstedelse af markedsføringstilladelse for Oslif Breezhaler.
The CHMP decided that Oslif Breezhaler’s benefits are greater than its risks and recommended that Oslif Breezhaler be given marketing authorisation.
CHMP besluttede, at fordelene ved Osseor opvejer risiciene, og anbefalede udstedelse af markedsføringstilladelse.
The CHMP decided that Osseor’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Ovitrelle er større end risiciene, og anbefalede udstedelse af markedsføringstilladelse for Ovitrelle.
The CHMP decided that Ovitrelle’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Pandemrix opvejer risiciene, og anbefalede udstedelse af markedsføringstilladelse for Pandemrix.
The CHMP decided that Pandemrix’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Pedea opvejer risiciene, og anbefalede udstedelse af markedsføringstilladelse for Pedea.
The CHMP decided that Pedea’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Pegasys opvejer risiciene, og anbefalede udstedelse af en markedsføringstilladelse.
The CHMP decided that Pegasys’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved PegIntron er større end risiciene, og anbefalede udstedelse af markedsføringstilladelse for PegIntron.
The CHMP decided that PegIntron’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Pergoveris opvejer risiciene, og anbefalede udstedelse af markedsføringstilladelse.
The CHMP decided that Pergoveris’s benefits are greater than its risks and recommended that it be given marketing authorisation.